Effect of medroxyprogesterone acetate on DMBA-induced rat mammary carcinoma and on immunological reactivity.
The antineoplastic activity of medroxyprogesterone acetate (MPA) was investigated in rats bearing DMBA-induced mammary carcinomas, a classical model of hormone-dependent tumor. Using a repeated injection schedule of relatively short duration, MPA was markedly effective (80% CR + PR) not only on relatively small (1-1.5 cm) tumors but also on advanced (4.5-5.5 cm) neoplasms. MPA effectiveness was comparable to that of a frankly toxic adriamycin regimen. In antitumorally effective schedules MPA was incapable of significantly affecting in either direction cellular and humoral immunological reactivities in rodents.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D005260:Female; D007109:Immunity / Q000187:drug effects*; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate; D051379:Mice; D009376:Neoplasms, Hormone-Dependent / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology; D051381:Rats
D000970:Antineoplastic Agents; D015127:9,10-Dimethyl-1,2-benzanthracene; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone